SMT201500174B - Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali - Google Patents
Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinaliInfo
- Publication number
- SMT201500174B SMT201500174B SM201500174T SM201500174T SMT201500174B SM T201500174 B SMT201500174 B SM T201500174B SM 201500174 T SM201500174 T SM 201500174T SM 201500174 T SM201500174 T SM 201500174T SM T201500174 B SMT201500174 B SM T201500174B
- Authority
- SM
- San Marino
- Prior art keywords
- triazolylpurins
- adenosine
- medicines
- useful
- receptor ligands
- Prior art date
Links
- 102000007471 Adenosine A2A receptor Human genes 0.000 title 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09155690 | 2009-03-20 | ||
| PCT/EP2010/053554 WO2010106145A1 (en) | 2009-03-20 | 2010-03-18 | Oxidated derivatives of triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201500174B true SMT201500174B (it) | 2015-10-30 |
Family
ID=40941572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201500174T SMT201500174B (it) | 2009-03-20 | 2015-07-20 | Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9133197B2 (es) |
| EP (1) | EP2408775B1 (es) |
| JP (1) | JP5648044B2 (es) |
| AR (1) | AR075894A1 (es) |
| DK (1) | DK2408775T3 (es) |
| ES (1) | ES2542555T3 (es) |
| HR (1) | HRP20150766T1 (es) |
| HU (1) | HUE025704T2 (es) |
| PL (1) | PL2408775T3 (es) |
| PT (1) | PT2408775E (es) |
| SI (1) | SI2408775T1 (es) |
| SM (1) | SMT201500174B (es) |
| TW (1) | TWI473809B (es) |
| WO (1) | WO2010106145A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49457A (fr) | 2017-06-22 | 2020-04-29 | Novartis Ag | Molécules d'anticorps se liant à cd73 et leurs utilisations |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| ES2927086T3 (es) * | 2017-09-28 | 2022-11-02 | Cstone Pharmaceuticals Suzhou Co Ltd | Derivado de anillo condensado como inhibidor del receptor A2A |
| BR112020008888A2 (pt) | 2017-11-16 | 2020-10-20 | Novartis Ag | terapias de combinação |
| US20200371091A1 (en) | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| WO2019178269A2 (en) | 2018-03-14 | 2019-09-19 | Surface Oncology, Inc. | Antibodies that bind cd39 and uses thereof |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| CN114450024A (zh) | 2019-09-16 | 2022-05-06 | 表面肿瘤学公司 | 抗cd39抗体组合物和方法 |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| MX2022003719A (es) | 2019-09-25 | 2022-04-26 | Surface Oncology Inc | Anticuerpos anti-il-27 y sus usos. |
| EP4076660A1 (en) | 2019-12-20 | 2022-10-26 | Novartis AG | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP2023548529A (ja) | 2020-11-06 | 2023-11-17 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3990061B2 (ja) * | 1998-01-05 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤 |
| US6579868B1 (en) | 1998-01-05 | 2003-06-17 | Eisai Co., Ltd. | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes |
| NZ516260A (en) * | 1999-07-02 | 2004-08-27 | Eisai Co Ltd | Fused imidazole compounds and remedies for diabetes mellitus |
| JP2004502640A (ja) * | 2000-02-10 | 2004-01-29 | ニューヨーク・ユニバーシティ | 肝繊維症、硬変症および脂肪肝を治療および予防するアデノシンａ２ａ受容体拮抗薬 |
| EP1401837B1 (en) * | 2001-06-29 | 2005-10-19 | Cv Therapeutics, Inc. | Purine derivatives as a2b adenosine receptor antagonists |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| WO2003020723A1 (en) * | 2001-08-30 | 2003-03-13 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE DERIVATIVE |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| JPWO2006129626A1 (ja) * | 2005-05-30 | 2009-01-08 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法 |
-
2010
- 2010-03-18 SI SI201030983T patent/SI2408775T1/sl unknown
- 2010-03-18 HR HRP20150766TT patent/HRP20150766T1/hr unknown
- 2010-03-18 ES ES10709526.7T patent/ES2542555T3/es active Active
- 2010-03-18 WO PCT/EP2010/053554 patent/WO2010106145A1/en not_active Ceased
- 2010-03-18 HU HUE10709526A patent/HUE025704T2/en unknown
- 2010-03-18 PT PT107095267T patent/PT2408775E/pt unknown
- 2010-03-18 JP JP2012500259A patent/JP5648044B2/ja not_active Expired - Fee Related
- 2010-03-18 DK DK10709526.7T patent/DK2408775T3/en active
- 2010-03-18 US US13/257,750 patent/US9133197B2/en not_active Expired - Fee Related
- 2010-03-18 EP EP10709526.7A patent/EP2408775B1/en active Active
- 2010-03-18 PL PL10709526T patent/PL2408775T3/pl unknown
- 2010-03-19 TW TW99108187A patent/TWI473809B/zh not_active IP Right Cessation
- 2010-03-19 AR ARP100100883A patent/AR075894A1/es unknown
-
2015
- 2015-07-20 SM SM201500174T patent/SMT201500174B/xx unknown
- 2015-08-10 US US14/822,252 patent/US20160002244A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI2408775T1 (sl) | 2015-08-31 |
| TW201100425A (en) | 2011-01-01 |
| WO2010106145A1 (en) | 2010-09-23 |
| PL2408775T3 (pl) | 2015-10-30 |
| US9133197B2 (en) | 2015-09-15 |
| JP2012520854A (ja) | 2012-09-10 |
| EP2408775A1 (en) | 2012-01-25 |
| HRP20150766T1 (hr) | 2015-08-14 |
| EP2408775B1 (en) | 2015-06-17 |
| TWI473809B (zh) | 2015-02-21 |
| DK2408775T3 (en) | 2015-07-27 |
| AR075894A1 (es) | 2011-05-04 |
| ES2542555T3 (es) | 2015-08-06 |
| PT2408775E (pt) | 2015-08-05 |
| US20120053191A1 (en) | 2012-03-01 |
| JP5648044B2 (ja) | 2015-01-07 |
| US20160002244A1 (en) | 2016-01-07 |
| HUE025704T2 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201500174B (it) | Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali | |
| SMT201500097B (it) | Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a | |
| CY2023012I1 (el) | Παραγωγα κινολιν-8-σουλφοναμιδιου εχοντα αντικαρκινικη δραση | |
| SMT201600198B (it) | Derivati di 1,2,4-triazina-4-ammina | |
| SMT201500036B (it) | Derivati di cromenone con attivita' antitumorale | |
| PL3043803T3 (pl) | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie | |
| SMT201500316B (it) | Derivati di benzotiazolo come agenti anticancro | |
| SMT201600225B (it) | DERIVATI DI 1,2,4-TIAZOLlDIN-3-0NE E LORO USO NEL TRATTAMENTO DEL CANCRO | |
| DK2192109T3 (da) | BICYKLISKE y-AMINOSYREDERIVATER | |
| HRP20182030T1 (hr) | Supstituirani nukleozidi, nukleotidi i njihovi analozi | |
| PL3133080T3 (pl) | Nowe cytostatyczne nukleozydy 7-deazapurynowe | |
| HRP20161562T1 (hr) | Derivati benzimidazola | |
| EP2875360A4 (en) | IN VITRO TEST FOR THE PREDICT OF RENALER PROXIMAL TUBULAR TOXICITY | |
| HRP20190572T1 (hr) | POSREDNIK ZA SINTEZU 1-(2-DEOKSI-2 FLUORO-4-TIO-beta-D-ARABINOFURANOZIL) CITOZINA, POSREDNIK ZA SINTEZU TIONUKLEOZIDA, I METODE ZA PROIZVODNJU OVIH POSREDNIKA | |
| SMT201400001B (it) | Derivati pirazolici usati come antagonisti del recettore CCR4 | |
| SI2872497T2 (sl) | Derivati kromanila za zdravljenje mitohondrijske bolezni | |
| SMT201600076B (it) | Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo | |
| SMT201300067B (it) | Applicazioni terapeutiche di derivati di chinazolindione | |
| SMT201400080B (it) | Derivati di pirazinoossazepina | |
| SMT201600262B (it) | Derivati benzazolici come ligandi del recettore h4 dell'istamina | |
| SMT201600405B (it) | Derivati di arilalchilamminocarbossammide fluorurati | |
| SMT201500182B (it) | Nuovi derivati di 8-idrossichinoline-7-carbossammidi terziarie e loro usi | |
| SMT201400157B (it) | Derivati di 2-piridin-2-il-pirazol-3(2H)-one, loropreparazione e loro uso terapeutico | |
| SMT201500113B (it) | Processp per preparare derivati di alfa-carbossammide | |
| DK2380892T3 (da) | Imidazothiazolderivat med prolinringstruktur |